Efficacy and Safety of PD-1/PD-L1 Inhibitor Versus Chemotherapy in First-line Treatment of Advanced Non-small Cell Lung Cancer: A Meta-analysis

Efficacy and Safety of PD-1/PD-L1 Inhibitor Versus Chemotherapy in First-line Treatment of Advanced Non-small Cell Lung Cancer: A Meta-analysis

Objective To review the effectiveness and safety of PD-1/PD-L1 inhibitor versus chemotherapy in the first-line treatment of advanced non-small cell lung cancer. Methods Relevant literatures were searched through Web of Science database, ASCO meeting abstract, journals, etc. for meta-analysis. Result...

Full description

Bibliographic Details
Main Authors:	WEI Yu, ZHANG Li
Format:	Article
Language:	zho
Published:	Magazine House of Cancer Research on Prevention and Treatment 2019-05-01
Series:	Zhongliu Fangzhi Yanjiu
Subjects:	pd-1/pd-l1 inhibitor chemotherapy first-line treatment advanced non-small cell lung cancer meta analysis
Online Access:	http://html.rhhz.net/ZLFZYJ/html/8578.2019.18.1190.htm

Similar Items

Adding PD-1/PD-L1 Inhibitors to Chemotherapy for the First-Line Treatment of Extensive Stage Small Cell Lung Cancer (SCLC): A Meta-Analysis of Randomized Trials
by: Francesco Facchinetti, et al.
Published: (2020-09-01)

Efficacy and safety of lenvatinib combined with PD-1/PD-L1 inhibitors plus Gemox chemotherapy in advanced biliary tract cancer
by: Chengpei Zhu, et al.
Published: (2023-01-01)

Efficacy and Safety of PD-1/PD-L1 Inhibitors Plus Chemotherapy Versus PD-1/PD-L1 Inhibitors in Advanced Non-Small Cell Lung Cancer: A Network Analysis of Randomized Controlled Trials
by: Xiang Li, et al.
Published: (2021-01-01)

PD-1/L1 inhibitor plus chemotherapy in the treatment of sarcomas
by: Zhichao Tian, et al.
Published: (2022-08-01)

Combining PD-1 or PD-L1 inhibitors with chemotherapy is a good strategy for the treatment of extensive small cell lung cancer: A retrospective analysis of clinical studies
by: Hao Luo, et al.
Published: (2022-12-01)

PD-(L)1 Inhibitors in Combination with Chemotherapy as First-Line Treatment for Non-Small-Cell Lung Cancer: A Pairwise Meta-Analysis
by: Jorge García-González, et al.
Published: (2020-07-01)

Comparison of efficacy and safety between PD-1 inhibitors and PD-L1 inhibitors plus platinum-etoposide as first-line treatment for extensive-stage small-cell lung cancer: a multicenter, real-world analysis
by: Yanrong Wang, et al.
Published: (2023-12-01)

PD-1/PD-L1 inhibitors plus anti-angiogenic agents with or without chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy as second or later-line treatment for patients with advanced non-small cell lung cancer: A real-world retrospective cohort study
by: Shubin Chen, et al.
Published: (2022-12-01)

Quality of life in patients with non-small cell lung cancer treated with PD-1/PD-L1 inhibitors: a systematic review and meta-analysis
by: Wei Liu, et al.
Published: (2022-10-01)

Addition of PD-1/PD-L1 inhibitors to chemotherapy for triple-negative breast cancer: a meta-analysis
by: Juan Yang, et al.
Published: (2024-02-01)

PD-1 inhibitors plus oxaliplatin or cisplatin-based chemotherapy in first-line treatments for advanced gastric cancer: A network meta-analysis
by: Xiaoyu Guo, et al.
Published: (2022-08-01)

Plasmatic Levels of HSP90α at Diagnosis: A Novel Prognostic Indicator of Clinical Outcome in Advanced Lung Cancer Patients Treated With PD-1/PD-L1 Inhibitors Plus Chemotherapy
by: Shubin Chen, et al.
Published: (2021-12-01)

Efficacy and Safety of PD-1/PD-L1 Checkpoint Inhibitors versus Anti-PD-1/PD-L1 Combined with Other Therapies for Tumors: A Systematic Review
by: Yiru Zhang, et al.
Published: (2023-01-01)

Discovery of Novel Small-Molecule Inhibitors of PD-1/PD-L1 Interaction via Structural Simplification Strategy
by: Hongbo Zhang, et al.
Published: (2021-06-01)

Outcomes With First-Line PD-1/PD-L1 Inhibitor Monotherapy for Metastatic Renal Cell Carcinoma (mRCC): A Multi-Institutional Cohort
by: Pedro Barata, et al.
Published: (2020-10-01)

PD-L1 Inhibitors as Monotherapy for the First-Line Treatment of Non-Small-Cell Lung Cancer in PD-L1 Positive Patients: A Safety Data Network Meta-Analysis
by: María Rosario García Campelo, et al.
Published: (2021-10-01)

Identification of CBPA as a New Inhibitor of PD-1/PD-L1 Interaction
by: Fengling Wang, et al.
Published: (2023-02-01)

Thyroid dysfunction (TD) induced by PD-1/PD-L1 inhibitors in advanced lung cancer
by: Yanling Wang, et al.
Published: (2024-03-01)

Research Advances of PD-1/PD-L1 Inhibitors Combined with Angiogenesis Inhibitors in Treatment of Advanced Triple-negative Breast Cancer
by: HUANG Shifen, et al.
Published: (2021-01-01)

Identifying optimal PD-1/PD-L1 inhibitors in first-line treatment of patients with advanced squamous non-small cell lung cancer in China: Updated systematic review and network meta-analysis
by: Mingye Zhao, et al.
Published: (2022-09-01)

Efficacy and safety of PD-1 and PD-L1 inhibitors combined with chemotherapy in randomized clinical trials among triple-negative breast cancer
by: Yihang Qi, et al.
Published: (2022-09-01)

PD-(L)1 Inhibitors as Monotherapy for the First-Line Treatment of Non-Small-Cell Lung Cancer Patients with High PD-L1 Expression: A Network Meta-Analysis
by: Margarita Majem, et al.
Published: (2021-03-01)

The benefit and risk of PD-1/PD-L1 inhibitors plus anti-angiogenic agents as second or later-line treatment for patients with advanced non-small-cell lung cancer: a systematic review and single-arm meta-analysis of prospective clinical trials
by: Shubin Chen, et al.
Published: (2023-08-01)

PD-1-mAb Plus Regimen in the First and Second Lines of Advanced and Unresectable Biliary Tract Carcinoma: A Real-World, Multicenter Retrospective Analysis
by: Wang F, et al.
Published: (2022-10-01)

Soluble PD-L1 changes in advanced non-small cell lung cancer patients treated with PD-1 inhibitors: an individual patient data meta-analysis
by: Takashi Shimizu, et al.
Published: (2023-11-01)

Clinical Outcomes for PD-1 Inhibitor Plus Chemotherapy as Second-Line or Later Therapy Compared to PD-1/PD-L1 Inhibitor Alone in Advanced Non-small-cell Lung Cancer
by: Xiaoyang Zhai, et al.
Published: (2020-09-01)

PD-1 inhibitor combined with chemotherapy for first-line treatment of esophageal squamous cell carcinoma patients with distant metastasis: a real-world retrospective study
by: Loulu Gao, et al.
Published: (2024-03-01)

Safety and Efficacy of Anti-PD-1/PD-L1 Inhibitors Compared With Docetaxel for NSCLC: A Systematic Review and Meta-Analysis
by: Long Ma, et al.
Published: (2021-08-01)

Corrigendum: Soluble PD−L1 changes in advanced non-small cell lung cancer patients treated with PD-1 inhibitors: an individual patient data meta-analysis
by: Takashi Shimizu, et al.
Published: (2023-12-01)

Evaluation of clinical efficacy, adverse reactions, and safety of PD-1 inhibitors combined with chemotherapy when treating advanced gastric cancer
by: Xue Huang, et al.
Published: (2023-11-01)

A Small Molecule Antagonist of PD-1/PD-L1 Interactions Acts as an Immune Checkpoint Inhibitor for NSCLC and Melanoma Immunotherapy
by: Yuanyuan Wang, et al.
Published: (2021-05-01)

Efficacy and safety of anlotinib combined with PD‐1/PD‐L1 inhibitors as second‐line and subsequent therapy in advanced small‐cell lung cancer
by: Lian Yu, et al.
Published: (2023-03-01)

Efficacy and safety of PD-1/PD-L1 inhibitor combined with chemotherapy versus chemotherapy alone in the treatment of advanced gastric or gastroesophageal junction adenocarcinoma: a systematic review and meta-analysis
by: Bo-Wei Liu, et al.
Published: (2023-04-01)

PD-1/PD-L1 Inhibitors as Monotherapy in the First-Line Treatment of Advanced Non-Small Cell Lung Cancer Patients with High PD-L1 Expression: An Expert Position Statement
by: Dolores Isla, et al.
Published: (2023-08-01)

The efficacy and safety of chemotherapy with or without anti‐PD‐1 for the first‐line treatment of advanced urothelial carcinoma
by: Fuxin Han, et al.
Published: (2023-12-01)

The Latest Findings of PD-1/PD-L1 Inhibitor Application in Gynecologic Cancers
by: Omid Kooshkaki, et al.
Published: (2020-07-01)

Treatment-Related Adverse Events with PD-1 or PD-L1 Inhibitors: A Systematic Review and Meta-Analysis
by: Yixi Zhang, et al.
Published: (2021-11-01)

Tumor response as defined by iRECIST in gastrointestinal malignancies treated with PD-1 and PD-L1 inhibitors and correlation with survival
by: Peiyi Xie, et al.
Published: (2021-11-01)

Efficacy and safety of PD-1/PD-L1 inhibitors in the treatment of recurrent and refractory ovarian cancer: A systematic review and a meta-analysis
by: Siyuan Zeng, et al.
Published: (2023-03-01)

Determining the optimal PD‐1/PD‐L1 inhibitors for the first‐line treatment of non‐small‐cell lung cancer with high‐level PD‐L1 expression in China
by: Meng‐Meng Teng, et al.
Published: (2021-09-01)